Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Government-Owned Inventions; Availability for Licensing 2008-09-05 (HHS Reference No. E-238-2008/2-PCT-01).
View Cancer Therapy Evaluation Program Intellectual Property Option to Collaborator Comments must be received by NIH on or before May 6, 2010.
View Prospective Grant of Exclusive License: Use of CD47 Antibodies, Antisense Oligonucleotides, and Small Molecules To Treat Disease Affecting the Vascular System Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 15, 2009 will be considered.
View Prospective Grant of Exclusive License: The Development of Thalidomide Analogs for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 20, 2009 will be considered.
View Prospective Grant of Exclusive License: Methods of Using Deacetylase Inhibitors To Treat Dystrophies and Other Tissue Degeneration Disorders Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 21, 2009 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Geldanamycin Derivative and Method of Treating Viral Infections Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 4, 2008, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: FDA Approvable Human Diagnostic for Osteoarthritis Only written comments and/or application for a license which is received by the NIH Office of Technology Transfer on or before March 21, 2006 will be considered.
View Prospective Grant of Exclusive License: Anthrax Lethal Factor Is a MAPK Kinase Protease Only license applications which are received by the National Institutes of Health on or before March 13, 2006 will be considered.
View Prospective Grant of an Exclusive License: Novel Isosteric Thalidomide Analogs With Enhanced TNF-α Inhibitory Activity Only written comments and/or license applications which are received by the National Institutes of Health on or before May 9, 2005 will be considered.
View Prospective Grant of Exclusive License: Methods and Compositions for the Promotion of Hair Growth Utilizing Actin Binding Peptides Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 24, 2004, will be considered.
View Government-Owned Inventions; Availability for Licensing
View National Institutes of Health Clinical Center (NIHCC); Opportunity for Cooperative Research and Development Agreement (CRADA) Interested parties should notify this office in writing of their intent to file a formal proposal no later than June 1, 2001. Formal proposals should be submitted to this office no later than July 2, 2001. Proposals received after this date will still be considered, but only after all proposals received before this date have been considered.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Identification and Development of Chemical Compounds That Interact With the Polo-Box of Polo Kinases, as Potential Therapeutic Targets for the Inhibition of Cellular Proliferation Interested parties should notify this office in writing of their interest in filing a formal proposal no later than January 2, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.